

**Table S1.** Baseline Characteristics of Study Participants According to Baseline Plasma 25(OH)D Concentrations

	25-hydroxyvitamin D			P-value
	< 10 ng/mL n=147	10-30 ng/mL n=763	> 30 ng/mL n=189	
Age (years)	65 ± 11	69 ± 11	71 ± 10	<0.001
Race (%)				
Black	54.9	30.5	15.7	<0.001
Diabetes (%)	62.5	55.9	45.0	0.001
Hypertension (%)	95.1	97.1	94.8	0.7
CVD (%)	54.9	56.2	60.7	0.3
BMI (kg/m <sup>2</sup> )	29.1 ± 5.4	28.1 ± 4.8	26.7 ± 4.4	<0.001
Systolic Blood Pressure (mmHg)	141 ± 24	144 ± 23	143 ± 23	0.6
eGFR (mL/min/1.73m <sup>2</sup> )	18 ± 7.0	18 ± 6.3	19 ± 6.4	0.1
Medication (%)				
ACE Inhibitor	45.1	41.1	38.2	0.2
Beta-blocker	59.7	59.7	58.1	0.7
Lipid-lowering	51.4	59.2	50.8	0.7
Albumin (g/dL)	3.9 ± 0.5	4.1 ± 0.5	4.3 ± 0.5	<0.001
Total Cholesterol (mg/dL)	183 ± 55	174 ± 42	165 ± 40	<0.001
HDL-C (mg/dL)	45 ± 16	42 ± 15	44 ± 13	0.6
LDL-C (mg/dL)	98 ± 37	95 ± 32	92 ± 33	0.09
Triglycerides (mg/dL)	198 ± 164	192 ± 140	144 ± 73	<0.001

Values are expressed as means ± standard deviation unless otherwise specified. Abbreviations:

25(OH)D=25-hydroxyvitamin D;

1,25(OH)<sub>2</sub>=1,25-dihydroxyvitamin D; CVD= cardiovascular disease; BMI= body mass index; iPTH=intact parathyroid hormone;

FGF23=fibroblast growth factor-23; eGFR=estimated glomerular filtration rate; ACE= angiotensin converting enzyme inhibitor;

HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol.

Note conversion factors for units: eGFR in ml/min/1.73m<sup>2</sup> to mL/s/1.73m<sup>2</sup> x0.01667; serum 25(OH)D in ng/mL to nmol/L x 2.496;

1,25(OH)<sub>2</sub>D in pg/mL to pmol/L x2.6; serum calcium in mg/dL to mmol/L x 0.2495; serum phosphorus in mg/dL to mmol/L x0.3229;

Serum hemoglobin in g/dL to g/L x 10; serum albumin in g/dL to g/L x 10; serum total cholesterol mg/dL in mmol/L x 0.02586;

Serum LDL-C in mg/dL to mmol/L x 0.02586; serum HDL-C in mg/dL to mmol/L x 0.02586; serum triglycerides in mg/dL to mmol/L

X 0.01129.